1. The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies
- Author
-
Tian, Guangming, Zhao, Xinliang, Nie, Jun, Dai, Ling, Hu, Weiheng, Zhang, Jie, Chen, Xiaoling, Han, Jindi, Ma, Xiangjuan, Wu, Di, Han, Sen, Long, Jieran, Wang, Yang, Zhang, Ziran, and Fang, Jian
- Subjects
Pulmonary and Respiratory Medicine ,Original Article - Abstract
BACKGROUND: Anaplastic lymphoma kinase (ALK) gene rearrangement is a series of mutations of non-small cell lung cancer (NSCLC) patients. Since 2011, multiple ALK inhibitors (ALKis) have been developed and launched for targeted therapy. In this study, we sought to investigate different strategies of sequential applying the ALKis and their clinical benefits to the overall survival (OS). METHODS: A total of 176 patients with advanced NSCLC (stage IIIB–IV) harboring the ALK rearrangement were included in this cohort study. They were diagnosed between February 1, 2012 and November 19, 2019 at Peking University Cancer Hospital. Clinical characters were reviewed from patients’ records. Strategies of drugs, progression-free survival (PFS) and OS were collected during the follow-ups. The Kaplan-Meier method and multivariate Cox proportional-hazard analysis were used to conduct the analyses survival and to examine the relationship between the variables and OS. RESULTS: A significantly longer OS was observed either in patients treated with crizotinib [N=106, median OS (mOS): 32.9 months] or in patients treated with a next-generation ALKi [N=34, mOS: not reached (NR)] as the initial ALKi, compared with patients treated with conventional chemotherapy but no ALKi (N=36, mOS: 10.3 months, P
- Published
- 2022